Kastritis, E
Gavriatopoulou, M
Roussou, M
Fotiou, D
Ziogas, D C
Migkou, M
Eleutherakis-Papaiakovou, E
Panagiotidis, I
Kanellias, N
Psimenou, E
Papadopoulou, E
Pamboucas, C
Manios, E
Gakiopoulou, H
Ntalianis, A
Tasidou, A
Giannouli, S
Terpos, E
Dimopoulos, M A
Article History
Received: 27 December 2016
Revised: 5 February 2017
Accepted: 15 February 2017
First Online: 16 June 2017
Competing interests
: EK—Genesis Parma: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Amgen: Consultancy, Honoraria. ET—BMS: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Other: Travel expenses, Research Funding; Celgene: Honoraria; Takeda: Consultancy, Honoraria; Genesis: Consultancy, Honoraria, Other: Travel expenses; Amgen: Consultancy, Honoraria, Other: Travel expenses, Research Funding; Novartis: Honoraria MAD: Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Onyx Pharmaceuticals: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Genesis: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. The other authors declare no conflict of interest.